Literature DB >> 17889144

Epidemiology and outcomes of multiple antibiotic-resistant bacterial infection in renal transplantation.

L Linares1, C Cervera, F Cofán, M J Ricart, N Esforzado, V Torregrosa, F Oppenheimer, J M Campistol, F Marco, A Moreno.   

Abstract

BACKGROUND: Mutiresistant bacterial infections are an emerging problem in the nosocomial setting. Our objectives were to describe the incidence, outcome, and risk factors for acquisition of multiresistant bacteria among renal transplant recipients.
METHODS: We prospectively followed patients undergoing kidney transplantation over a 3-year period. We collected demographic features, underlying chronic diseases, and main transplant characteristics and complications. Multiple antibiotic resistance was defined for the most important bacteria: Enteric gram-negative bacilli resistant to betalactamics, cephalosporins, and quinolones; Staphylococcus aureus resistant to methicillin, cotrimoxazole, and clindamcin; Enterococcus spp resistant to ampicillin and quinolones; nonfermentator bacilli resistant to all antibiotics except aminoglycosides and collistin.
RESULTS: Overall, 416 patients included 65 double transplants (62 kidney-pancreas and three kidney-liver) of mean age 48.5 years, and 57% men. Infection with multiresistant bacteria was observed in 58 patients (14%). Most frequent multiresistant bacteria were: Escherichia coli (n = 33), Klebsiella spp (n = 15), Citrobacter spp (n = 8), Enterobacter spp (n = 5), Morganella morganii (n = 2), Pseudomonas aeruginosa (n = 16), Acinetobacter baumanii (n = 2), Enterococcus spp (n = 9) and methicillin-resistant S. aureus (MRSA, n = 2). Age greater than 50 years, hepatitis C virus infection, double kidney-pancreas transplantation, requirement for posttransplant hemodialysis, surgical reoperation, and requirement for nephrostomy were independent variables associated with multiresistant bacterial infection. Most used antibiotics for treatment were: carbapenems (65%), amikacin (12%), linezolid, piperacillin-tazobactam, vancomycin, collistin, and fosfomycin. Infection with multiresistant bacteria was associated with a worse prognosis (graft loss or death, 19% vs 8%, P = .009).
CONCLUSIONS: The incidence of infection with multiresistant bacteria in our renal transplant cohort was high, being most frequently cephalosporin-resistant enteric gram-negative bacilli and multiresistant P aeruginosa. Methicillin-resistant S. aureus incidence was low. Infection with multiresistant bacteria conferred a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17889144     DOI: 10.1016/j.transproceed.2007.06.061

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  18 in total

1.  Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation.

Authors:  Oluwadamilola A Adeyemi; Chao Qi; Teresa R Zembower; Michael G Ison; Thomas H Grant; Brian J Hartigan; Michael Malczynski; Valentina Stosor
Journal:  J Clin Microbiol       Date:  2008-06-04       Impact factor: 5.948

2.  Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors:  Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 3.  Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.

Authors:  Q Q Wan; Q F Ye; H Yuan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-12       Impact factor: 3.267

4.  Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: Results from a Spanish multicenter cohort.

Authors:  María Ruiz-Ruigómez; Mario Fernández-Ruiz; José Tiago Silva; Elisa Vidal; Julia Origüen; Antonia Calvo-Cano; Enrique Luna-Huerta; Esperanza Merino; Domingo Hernández; Cristina Jironda-Gallegos; Rosa Escudero-Sánchez; Francesca Gioia; Antonio Moreno; Cristina Roca; Elisa Cordero; Darío Janeiro; Beatriz Sánchez-Sobrino; María Milagro Montero; Dolores Redondo; Francisco Javier Candel; Isabel Pérez-Flores; Carlos Armiñanzas; Claudia González-Rico; María Carmen Fariñas; Emilio Rodrigo; Belén Loeches; María O López-Oliva; Miguel Montejo; Ricardo Lauzurica; Juan Pablo Horcajada; Julio Pascual; Amado Andrés; José María Aguado; Francisco López-Medrano
Journal:  Antimicrob Agents Chemother       Date:  2021-02-08       Impact factor: 5.191

Review 5.  Updates on urinary tract infections in kidney transplantation.

Authors:  Marco Fiorentino; Francesco Pesce; Antonio Schena; Simona Simone; Giuseppe Castellano; Loreto Gesualdo
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

6.  Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients.

Authors:  Marcelo M Mostardeiro; Carlos A P Pereira; Alexandre R Marra; Jose O M Pestana; Luis Fernando A Camargo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 7.  Antimicrobial resistance in nephrology.

Authors:  Tina Z Wang; Rosy Priya L Kodiyanplakkal; David P Calfee
Journal:  Nat Rev Nephrol       Date:  2019-08       Impact factor: 28.314

Review 8.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

Review 9.  Infectious disease risks in pediatric renal transplantation.

Authors:  Felicia A Scaggs Huang; Lara Danziger-Isakov
Journal:  Pediatr Nephrol       Date:  2018-04-06       Impact factor: 3.651

10.  Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018.

Authors:  Philipp Kohler; Aline Wolfensberger; Susanne Stampf; Andreas Brönnimann; Katia Boggian; Christian van Delden; Melody Favre; Cédric Hirzel; Nina Khanna; Stefan P Kuster; Oriol Manuel; Dionysios Neofytos; Silvio Ragozzino; Peter W Schreiber; Laura Walti; Nicolas J Mueller
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-07       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.